Old Web
English
Sign In
Acemap
>
authorDetail
>
Nathalie Fagniez
Nathalie Fagniez
Antibody
Population
Biology
Pharmacokinetics
Antibody-drug conjugate
3
Papers
14
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates
2017
The Journal of Clinical Pharmacology
Marion Bouillon‐Pichault
Claire Brillac
Céline Amara
Céline Nicolazzi
Nathalie Fagniez
Jean‐Baptiste Fau
Kimiko Koiwai
Samira Ziti-Ljajic
Christine Veyrat‐Follet
Show All
Source
Cite
Save
Citations (7)
Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma (NCT00796731).
2017
Journal of Clinical Oncology
Bertrand Coiffier
Franck Morschhauser
Jehan Dupuis
Corinne Haioun
Fabrice Lainé
Roch Houot
Hervé Tilly
Oana Brehar
John M. Lambert
Nathalie Fagniez
Sandrine Payrard
Vincent Ribrag
Show All
Source
Cite
Save
Citations (6)
Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model
2015
Molecular Cancer Therapeutics
Christophe Henry
Céline Nicolazzi
Céline Amara
Anne-Marie Lefebvre
Christelle Larois
Florence Attenot
Claire Brillac
Marion Bouillon‐Pichault
Nathalie Fagniez
Stephanie Decary
Cécile Combeau
Pierre-Francois Berne
Souad Naimi
Marielle Chiron
Veronique Blanc
Show All
Source
Cite
Save
Citations (1)
1